Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
2–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
2-18 years of age
Group A: Lamivudine naive (\<1 week of Lamivudine) and not within 24 weeks of screening; Group B: Lamivudine experienced (\> 12 weeks of Lamivudine); Group C: nucleoside/nucleotide experienced (\> 12 weeks of nucleoside/tide therapy) added as a country-specific protocol amendment (not all sites had Group C).
HBV Deoxyribonucleic acid (DNA) ≥ 100000 copies/mL; ≥ 10000 copies for nucleoside/nucleotide experienced (Group C)
Detectable Hepatitis B surface antigen (HBsAg) for 24 weeks prior to screening
Hepatitis B e antigen (HBeAg) positive
Compensated liver and renal function
Elevated alanine aminotransferase (ALT) at screening and during the 24 weeks prior to screening (for Groups A and B)
You may not be if
Coinfection with Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Hepatitis D Virus (HDV)
Children who were breastfed while their mother received Lamivudine, or children whose mothers received Lamivudine during pregnancy
Clareo Health | A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection
